Gary E. Frashier
Board of Directors
Mr. Frashier is President and Principal of Management Associates, and he brings extensive experience in life science management, operations and transactions, having served as a CEO for twenty-four years in life sciences and specialty chemicals.
Prior to the founding of Management Associates, Mr. Frashier served as Chief Executive Officer and Chairman of OSI Pharmaceuticals, and it was during his tenure at OSI that the leading genetic-based cancer drug, "Tarceva" was discovered and developed thru initial human Proof of Concept clinical trials.
Mr. Frashier has raised over $250 million from a combination of equity financings and other sources, has organized many collaborations and joint programs with major pharmaceutical companies, and has served as a founder of several life science companies.
Prior to OSI, Mr. Frashier served as President, International, and Executive Vice President of Millipore Corporation; President and CEO of Waters Corporation, the leader in liquid chromatography; and CEO of Genex Corporation, a protein engineering company.
has participated as a founder in organizing several biotechnology companies, including Merrimack Pharmaceuticals, Inc.; Eutropics, Inc.; America Stem Cell, Inc.; and Apex BioVentures Acquisition Corporation
He currently serves on the Board of Directors of Achillion Pharmaceuticals, Inc. (NASDAQ), ViroXis Corporation, Inc., and Metric Medical Devices, Inc., and he is an Advisor to Santalis Corporation and StemBioSys.
He is a Strategic Partner in SV Life Sciences LP, a major venture capital company.
He has served on numerous other private and public life science company Boards, including Maxim Pharmaceuticals, Tekmira Pharmaceuticals (Canada), Apex BioVentures Acquisition Corporation, Tanox, Inc., Cytoclonal Pharmaceuticals, Exegenics Pharmaceuticals, Aderis Pharmaceuticals, and Alseres Pharmaceuticals.
Mr. Frashier has a B.S. in Chemical Engineering from Texas Tech University, which has designated him a "Distinguished Engineer Graduate," and an M.B.A. from the Massachusetts Institute of Technology, where he was selected as an "Alfred P. Sloan Fellow.